<DOC>
	<DOCNO>NCT01098877</DOCNO>
	<brief_summary>The study evaluate hypothesis dos plasma concentration affect pharmacodynamic marker activity chemokine receptor , CCR2 CCR5 , compound safe well tolerate . It also evaluate hypothesis pharmacokinetic profile robust consistent twice day therapeutic administration .</brief_summary>
	<brief_title>First In Human Study Of Increasing Oral Doses Of PF-04634817</brief_title>
	<detailed_description />
	<criteria>Healthy male female ( nonchild bear potential ) subject 18 55 year age . Body mass index 17.5 30.5 kg/m2 total body weight &gt; 50kg . Evidence history clinically significant disease . Treatment investigational drug within 30 day study start Use prescription nonprescription medicine within 7 day study start</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Phase1</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>safety</keyword>
	<keyword>toleration</keyword>
	<keyword>pharmacodynamics</keyword>
</DOC>